Nalbuphine ER:  Relief is Possible

We are developing Nalbuphine ER unlocking new market opportunities and the potential to significantly improve the quality of life of patients suffering from the serious symptoms associated with chronic neurologically mediated conditions.

Passionate
about Progress

Backed by expert scientific and medical advisors and dedicated to our investors, the Trevi leadership team is highly engaged and experienced in life science clinical development, successful commercialization, and building companies of exceptional value.

Passionate
about Progress

Backed by expert scientific and medical advisors and dedicated to our investors, the Trevi leadership team is highly engaged and experienced in life science clinical development, successful commercialization, and building companies of exceptional value.

Are you suffering from or caring for someone with symptoms associated with chronic neurologically mediated conditions?

A New Hope for Patients with Chronic and Serious Neurologically Mediated Conditions

We are developing Nalbuphine ER as an oral treatment for a broad range of chronic conditions for which patients have few, if any, treatment options. With its unique dual mechanism of action, Nalbuphine ER has the potential to significantly improve the quality of life of patients.

Committed to Excellence in Pharmaceutical Development and Bringing Solutions to Patients

news

08/06/2020

Conference Call and Webcast to be Held at 4:30 p.m. ET NEW HAVEN, Conn. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious

08/05/2020

NEW HAVEN, Conn. , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management

07/13/2020

Independent Data Monitoring Committee Recommends Continuation of PRISM Trial with Expansion to 360 Subjects per the Adaptive Design Enrollment Expected to be Complete by Third Quarter 2021 Introducing HADUVIO ™ as Proposed Trade Name for Nalbuphine ER   NEW HAVEN, Conn.

contact

Trevi Therapeutics

195 Church Street, 14th Floor
New Haven, CT 06510
map

(203) 304-2499
email us